CARB-X provides funding to support research into the development of antibiotics, vaccines, diagnostics, devices, and other life-saving products to respond to the threat of drug-resistant bacteria.
Funding & Duration
Funding amount and duration is variable, and dependent on the individual project.
The scope of CARB-X funding is restricted to projects that target drug-resistant bacteria highlighted on the ‘Antibiotic Resistant Threats in the United States’ report published by the Centers for Disease Control and Prevention (CDC) in 2013 or the Priority Bacterial Pathogens list published by the World Health Organization (WHO) in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list.
CARB-X supports early development of innovative products within the following categories in descending priority: direct-acting therapeutics for Gram-negative infections, diagnostics, prevention (includes vaccines, microbiome, devices, etc.), indirect acting therapeutics, and direct-acting therapeutics for Gram-positive infections.
CARB-X welcomes applications from around the world.
Please refer to the Sponsor’s website for further details regarding eligibility.
Submission Requirements & Due Date
- Expressions of Interest must be submitted for internal review by 23 March 2018
- Please email email@example.com if you are considering applying for this scheme.
- Submit an Application to Research Services for Review